ClinicalTrials.gg
RecruitingNCT07339111CARTISTEM23-01Updated Nov 18, 2026

Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis

A Phase 3 interventional study of CARTISTEM® + Debridement and Debridement in Knee Cartilage Defects, sponsored by Medipost, Inc.. Recruiting at 40 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Medipost, Inc. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 18, 202610 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,029 studies in Osteoarthritis with a site in United States — 116 open to participants now, 175 under way, 14 of them phase 3. Osteoarthritis · United States.

Planned enrollment
176th of 832
300 · median 100
Started
2026
with 35 others
Phase 3
128 of 1,029
8 open now
Primary completion
2029-06
later than 143 of 174 live
Registered
1,008th of 1,029
by date

Among the 1,029 studies in Osteoarthritis with a site in United States, this one is the 176th largest by planned enrollment of the 832 interventional ones that give a count, is one of 36 that started in 2026, is one of 128 in phase 3, reaches primary completion later than 143 of the 174 other live ones, and was the 1,008th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

116 of the 1,029 studies in Osteoarthritis with a site in United States are open now. Recruiting first, the newest first:

110 more — sign in →

All 116 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,029 studies in Osteoarthritis with a site in United States, or all of them as a file.
02

Study summary

This study will test whether CARTISTEM is safe and works better than debridement (a surgery that cleans out damaged tissue) for people with knee cartilage damage and osteoarthritis.

CARTISTEM is a new treatment made of stem cells from donated umbilical cord blood mixed with a gel (hyaluronic acid) that is placed in the damaged area of the knee

The main goal is to find out if CARTISTEM® reduces knee pain and improves knee function more than debridement two years after treatment. The study will also use MRI scans to explore whether CARTISTEM® may slow the worsening of osteoarthritis over time.

Read the detailed description

To establish the efficacy and safety of CARTISTEM®, a combination product composed of allogeneic human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) formulated with a cross-linked sodium hyaluronate (HA) hydrogel, CARTISTEM® compared to the surgical comparator of debridement in Subjects with knee cartilage lesions and osteoarthritis.

This trial is intended to provide evidence of the superiority of CARTISTEM® to reduce knee pain and improve knee function compared to debridement for Subjects with knee cartilage lesions and osteoarthritis at 2-years post-treatment.

Additionally, this trial is intended to intended to explore whether CARTISTEM® may have disease-modifying effects on osteoarthritis progression through the use of semi-quantitative MRI assessment.

03

Conditions studied

  • Knee Cartilage Defects

Browse trials for

Keywords

  • symptomatic knee cartilage defects
  • knee cartilage
  • cartilage repair
  • osteoarthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 and ≤ 75 years old.
  2. Knee Osteoarthritis diagnosed in the index knee according to the clinical definition of American College of Rheumatology (ACR) guidelines at screening.
  3. Failed conservative knee osteoarthritis treatment for at least 3 months prior to consent (weight reduction, physical therapy, injections, pain medications, etc.).
  4. Kellgren-Lawrence (KL) in the index knee of grade 2 to 3 as determined by independent radiologist review of study X-Ray.
  5. femoral cartilage defects classified using modified Outerbridge Grade 3 or 4 in index knee with combined lesion area ≥ 2 cm2 and ≤ 9 cm2 and at least a single femoral lesion ≥ 2 cm2 as determined by independent radiologist review of study MRI.
  6. (BMI) ≤ 35 kg / m2 .
  7. VAS PAIN index knee score ≥ 40 to ≤ 90 based on 100-point scale at screening.
  8. VAS PAIN contralateral knee score ≤ 30 based on 100-point scale at screening.
  9. WOMAC® FUNCTION index knee mean score ≥ 25 to ≤ 90 based on 100-point scale at screening.
  10. WOMAC® Pain index knee mean score ≥ 40 to ≤ 90 based on 100-point VAS (visual analogue scale) at screening.
  11. Subjects must be willing to abstain from treatments in the index knee from the time the is signed until after the last study follow up visit.
  12. Subjects must be willing to discontinue analgesics except:

    • Rescue medication (acetaminophen) allowed for break-through pain throughout the study.
    • Subjects must be willing to discontinue use of all pain medications at least 48 hours prior to baseline assessment and each follow up visit.
    • Limited postoperative NSAID use is permissible per IND clinical guidance and site manual, provided before scheduled efficacy assessments.
    • Post operative narcotics.
  13. Subjects with stage 3 hypertension (systolic ≥ 180 mm Hg and diastolic ≥ 120 mmHg) must have blood pressure (BP) controlled prior to surgical procedure.
  14. Subject's central lab results are within normal ranges or deemed as not clinically significant by investigator for CARTISTEM® treatment or surgical comparator.
  15. Female Subjects of must agree to practice adequate methods of to prevent pregnancy during the study.
  16. Subjects must be able to comply fully with the rehabilitation requirements.
  17. Subjects must be able to understand and comply with the requirements of the study.
  18. Subjects must voluntarily provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Subject received an IA injection of Hyaluronic Acid (HA), Rich Plasma (PRP), Bone Marrow Aspirate / Concentrate (BMA / BMAC), long-acting / conventional , or drug in either knee within 3 months of signing . Note: injections of the contralateral knee are allowed during the trial.
  2. Bone marrow lesion (BML) grade 3 on femur, tibia, or patella except at femoral lesion area (BML grade 3 allowed) in index knee as determined by independent radiologist review of study MRI.
  3. KL index knee grade 0, 1 or 4 as determined by independent radiologist review of study X-Ray.
  4. KL Contralateral knee severity grade 4 as determined by independent radiologist review of study X-Ray.
  5. Anatomical axis varus or valgus malalignment ≥ 6° in either knee as determined by independent radiologist.
  6. Joint ligament instability in index knee ≥ Grade 3 or ligament instability that would require surgical intervention as determined by investigator or designee.
  7. Complete meniscal deficiency, meniscal root tears and / or severe meniscal extrusion as determined by independent radiologist.
  8. Kissing bipolar lesions (tibial or patellar) Outerbridge 4 exceeding 25% of the femoral lesion area in size and/or penetrating through the subchondral bone as determined by independent radiologist.
  9. Surgery of the index knee joint within 6 months of signing the informed consent. Investigator confirms that Subject has recovered from any prior surgical intervention to enable treatment within this study protocol. No radiation therapy of the index knee as determined by documented medical history.
  10. Chronic inflammatory articular diseases such as rheumatoid arthritis, gout, pseudogout, gouty arthritis, or fibromyalgia as determined by documented medical history.
  11. Bone disorders of index knee: osteonecrosis including avascular necrosis (AVN); Osteochondritis dissecans (OCD); Spontaneous Osteonecrosis of the Knee (SONK); Subchondral Insufficiency Fracture (SIF); Subchondral / intraosseous bone cyst >4mm at femoral treatment location, bone tumors, bone contusion or stress fracture, pathologic fracture, and other bone exclusionary findings as determined by independent radiologist review of study MRI or X-ray.
  12. Joint disorders of the index knee including infection, osteomyelitis, soft tissue tumors, and bone marrow infiltration as determined by independent radiologist review of study MRI or X-ray.
  13. Diseases or disorders including Paget's disease, ochronosis, acromegaly, haemochromatosis, Wilson's disease, genetic disease (hyperkinesia, etc.), or genetic collagen disorder as determined by documented medical history.
  14. Vascular or neurological disorders of the lower extremities as determined by documented medical history. Note: Varicose veins are not an exclusion criteria.
  15. diseases - documented medical history. Addison's Disease, Dermatomyositis, Irritable Bowel Diseases (IBD) or Irritable Bowel Syndrome (IBS) (including Crohn's disease and ulcerative colitis), Multiple sclerosis, Myasthenia gravis, Pernicious anemia, Rheumatoid Arthritis, Sjogren's Syndrome, systemic Lupus erythematosus. Note: Celiac disease is not an exclusion criterion.
  16. Subject has documented systemic diseases such as but not limited to , hepatitis, HTVL, syphilis, and blood coagulopathies (including hemophilia, Von Willebrand disease, thrombocytopenia, disseminated intravascular coagulation (DIC)). Note: Occurrence of Deep Vein Thrombosis ≥ 5 years prior to consent is not an exclusion.
  17. Subject is taking anticoagulant medication (e.g., warfarin, (Coumadin), apixaban (Eliquis), rivaroxaban (Xarelto), clopidogrel (Plavix) or equivalent) but not excluding 81mg aspirin.
  18. Uncontrolled diabetes with > 8% as determined by documented medical history.
  19. Infectious disease requiring parenteral administration of antibiotics.
  20. Administered such as Cyclosporin A or azathioprine within 6 months of signing the informed consent.
  21. Subject has received chemotherapy in the 12 months prior to signing informed consent.
  22. Subject has received other allogeneic stem cell therapy.
  23. Prior cartilage repair procedure (such as MACI, ACI, OATS, OCA, Agili-C) in the index knee or the index knee contains a uni-compartmental knee replacement. Revision of a prior microfracture procedure is allowed if subchondral plate remains intact and lesion is lacking significant intra-lesional osteophytes.
  24. Prior invasive knee osteoarthritis treatment including subchondroplasty, cryoneurolysis, genicular nerve ablation, genicular artery embolization, in situ MISHA (medial knee implanted shock absorber), prosthetic implants or other knee implants or invasive treatments for the index knee.
  25. Known history of / allergy to hyaluronan.
  26. Currently pregnant or nursing.
  27. Psychotic diseases, epilepsy, or any history of such diseases.
  28. Known substance or alcohol abuse in the prior 3 years.
  29. to MRI imaging or unwillingness to undergo MRI.
  30. Currently receiving or in litigation related to workman's compensation, personal injury, or disability claims.
  31. Considered by principal investigator inappropriate for the clinical trial due to any reasons other than those listed above.

Baseline PRO Assessment Inclusion Criteria:

  1. VAS PAIN index knee score ≥ 40 to ≤ 90 based on 100-point scale at baseline PRO assessment.
  2. WOMAC® FUNCTION index knee mean score ≥ 25 to ≤ 90 based on 100-point scale at baseline PRO assessment.

Baseline Surgical Inclusion Criteria:

1. Treated cartilage defects Outerbridge Grade 3 or 4 in index knee with combined femoral lesion area ≤ 9 cm2 as determined arthroscopically or by arthrotomy by treating physician.

Baseline Surgical Exclusion Criteria:

  1. Meniscal root tears and / or severe meniscal extrusion or non-functional meniscus as determined arthroscopically or by arthrotomy by treating physician.
  2. Kissing bipolar lesions (tibial or patellar) Outerbridge 4 exceeding 25% of the femoral lesion area in size and/or penetrating through the subchondral bone as determined arthroscopically or by arthrotomy by treating physician.
  3. Bone or joint disorders of the index knee including infection, osteomyelitis, soft tissue tumors, bone marrow infiltration, osteonecrosis (AVN or OCD) as determined arthroscopically or by arthrotomy by treating physician.
  4. Identification of prior cartilage repair procedure (such as MACI, ACI, OATS, OCA, Agili-C) or uni-compartmental knee replacement in the index knee as determined arthroscopically or by arthrotomy by treating physician. Revision of a prior microfracture procedure is allowed if subchondral bone remains intact and lacking significant intra-lesional osteophytes.
  5. Subject is documented as pregnant based on hCG urine or blood test prior to surgery.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    CARTISTEM + Debridement

    Participants in Group A will receive CARTISTEM + Debridement in the target knee.

    Biological: CARTISTEM® + Debridement

  • Active comparator
    Debridement

    Participants in Group B will receive debridement procedure.

    Procedure: Debridement

Interventions

  • BiologicalCARTISTEM® + Debridement

    CARTISTEM group: CARTISTEM is made of two parts supplied in separate vials: (1) about 7.5 million stem cells from human umbilical cord blood (hUCB-MSCs ) suspended in 1.5 ml of liquid medium, and (2) 60 mg of sodium hyaluronate, a gel-forming substance, supplied as a freeze-dried powder. The two parts are mixed together to form a thick, moldable gel that is placed in the damaged area of the knee. During surgery small holes are made into the bone where the arthritis exists to stimulate the patient's bone marrow, so the stem cells can interact and re-grow the missing cartilage. Is important to note that the stem cells do not cause an immune response and the patient will grow their own cartilage.

  • ProcedureDebridement

    Debridement is a standard surgical procedure for knee cartilage damage. It is done arthroscopically (through small incisions with a camera and instruments) or through a small open incision. The surgeon removes damaged cartilage and unstable tissue from the knee and smooths the edges.

06

What researchers measure

Primary outcomes

  1. Visual Analog Scale (VAS) Pain Score

    Change from Baseline Visual Analog Scale (VAS) Pain score (0-100 point scale, 0 being no pain at one end and 100 being the worst imaginable pain at the other) in index knee comparing CARTISTEM® to surgical control at 24-months post-treatment.

    Time frame: From enrollment to end of follow-up at 24 months

  2. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC®) Function score

    Change from Baseline Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC®) Function score (0-100 point scale, 0 being the best functioning and 100 being the worst functioning) in index knee comparing CARTISTEM® to surgical control at 24-months post-treatment.

    Time frame: From start of treatment to the end of follow-up at 24 months

Secondary outcomes

  1. Modified Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) Score

    Change in modified MOCART score in Index knee comparing CARTISTEM® to surgical control at 24-months post-treatment.

    Time frame: enrollment to follow-up at 24 months.

  2. Change in MRI Osteoarthritis Knee Score (MOAKS) cartilage morphology

    Change in MOAKS cartilage morphology with delta sum score - extent of cartilage damage score in Index knee comparing CARTISTEM® to surgical control at 24-months post-treatment.

    Time frame: enrollment to follow up at 24 months

Other outcomes

  1. Change in Western Ontario and McMaster Universities OA Index (WOMAC®) Total score (0-100 point scale, 0 being no osteoarthritis symptoms and 100 being the worst symptoms) in index knee comparing CARTISTEM® to surgical control at 24-months post-treatment.

    Time frame: enrollment to follow up at 24 months

  2. Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC®) Stiffness score (0-100 point scale, 0 being the no stiffness, 100 being the most) in index knee comparing CARTISTEM® to surgical control at 24-months post-treatment.

    Time frame: enrollment to follow up at 24 months

  3. Change in EuroQoL 5 Dimensions, 5 Levels (5D-5L, with 0 being the worst and 100 being the best) comparing CARTISTEM® to surgical control at 24-months post-treatment.

    Time frame: enrollment at follow up at 24 months

  4. Change in MOAKS intercondylar synovitis comparing CARTISTEM® to surgical control at 24-months post-treatment.

    Time frame: enrollment to follow up at 24 months

  5. Change in MOAKS whole knee effusion comparing CARTISTEM® to surgical control at 24-months post-treatment.

    Time frame: enrollment to follow up at 24 months

  6. Change in MRI Osteoarthritis Knee Score (MOAKS) cartilage morphology - extent of cartilage damage comparing CARTISTEM® to surgical control at 24-months post-treatment

    Time frame: Enrollment to follow up at 24 months

  7. Change in Evaluator Global Assessment (0-100, 0 being very well, 100 being very poor) comparing CARTISTEM® to surgical control at 24-months post-treatment.

    Time frame: Enrollment to follow up at 24 months

  8. Change in Patient Global Assessment (0-100, 0 being very well, 100 being very poor) comparing CARTISTEM® to surgical control at 24-months post-treatment.

    Time frame: Enrollment to follow up at 24 months.

  9. OMERACT-OARSI responder rate comparing CARTISTEM® to surgical control at 24-months post-treatment.

    Time frame: Enrollment to follow up at 24 months

  10. Treatment failure rate comparing CARTISTEM® to surgical control at 24-months post-treatment.

    Time frame: Enrollment to follow up at 24 months

07

Study locations

39 of 40 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

5 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2029, 39 months after the start.

Of 60 industry-sponsored phase 3 interventional studies under Osteoarthritis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 22. This study's planned 39 months is above that.

Counting every sponsor, half of 84 studies reached it within 17 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2026
First posted
Jan 14, 2026
StartActual
Mar 11, 2026
Primary completionEst.
Jun 30, 2029
CompletionEst.
Jun 30, 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites added
Show 10 added (10 United States)
  • Stanford University - Department of Orthopaedic Surgery · Redwood City, United States
  • Advanced Research · Deerfield Beach, United States
  • Sports and Orthopedic Center · Deerfield Beach, United States
  • University of Nebraska Medical Center · Omaha, United States
  • NYU Langone Orthopedic Center · New York, United States
  • University of California, San Francisco - Orthopaedic Institute · San Francisco, United States
  • University of Utah · Salt Lake City, United States
  • UCI Alpha Clinic · Irvine, United States
  • Bioresearch Partner · Miami, United States
  • Mercy Health Orthopedics and Sports Medicine Institute · Cincinnati, United States
across 4 updates, Oct 6, 2026 – Nov 18, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • JBR Clinical Research · Salt Lake City, United StatesContact h•••@cenexel.com · •••2000→w•••@cenexel.com · •••2000
Nov 5, 2026
Show all 5 updates
  1. Nov 18, 2026
    3 sites added
    Show 3 added (3 United States)
    • UCI Alpha Clinic · Irvine, United States
    • Bioresearch Partner · Miami, United States
    • Mercy Health Orthopedics and Sports Medicine Institute · Cincinnati, United States
  2. Nov 5, 2026
    2 sites added
    Show 2 added (2 United States)
    • University of California, San Francisco - Orthopaedic Institute · San Francisco, United States
    • University of Utah · Salt Lake City, United States
    Site contacts Changed at 1 site. See the sites
    Show the site
    • JBR Clinical Research · Salt Lake City, United StatesContact h•••@cenexel.com · •••2000→w•••@cenexel.com · •••2000
  3. Oct 29, 2026
    Minor edits only
    + 2 other changes: description and arm descriptions
  4. Oct 20, 2026
    4 sites added
    Show 4 added (4 United States)
    • Advanced Research · Deerfield Beach, United States
    • Sports and Orthopedic Center · Deerfield Beach, United States
    • University of Nebraska Medical Center · Omaha, United States
    • NYU Langone Orthopedic Center · New York, United States
  5. Oct 6, 2026
    1 site added
    Show site
    • Stanford University - Department of Orthopaedic Surgery · Redwood City, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07339111
Lead sponsor
Medipost, Inc.
Responsible party
Sponsor
First posted
Jan 14, 2026
Start date
Mar 11, 2026
Primary completion
Jun 30, 2029 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Adrian Orr, VP Clinical Development
Contact
cartistem2023-01@medi-post.com
617-575-2203
Luis Toro, Medical Monitor for IQVIA, MD
Contact

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion